Heinz Hammerlindl

Heinz Hammerlindl

Auto-generated profile, based on publicly available information

Heinz Hammerlindl

Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAlexander Bogdanov
Alexander Bogdanov
MSMariam N. Salib
Mariam N. Salib
ACAlexander B. Chase
Alexander B. Chase
HHHeinz Hammerlindl
Heinz Hammerlindl
MMMitchell Muskat
Mitchell Muskat
PJPaul Jensen
Paul Jensen
Culture-based microbial natural product discovery strategies fail to realize the extraordinary biosynthetic potential detected across earth’s microbiomes. Here we introduce Small Molecule In situ Resin Capture (SMIRC), a culture-independent method to obtain natural products directly from the environments in which they are produced. We use SMIRC to capture numerous compounds including two new carbon skeletons that were characterized using NMR and contain structural features that are, to the best of our knowledge, unprecedented among natural products. Applications across diverse marine habitats reveal biome-specific metabolomic signatures and levels of chemical diversity in concordance with sequence-based predictions. Expanded deployments, in situ cultivation, and metagenomics facilitate compound discovery, enhance yields, and link compounds to candidate producing organisms, although microbial community complexity creates challenges for the later. This compound-first approach to natural product discovery provides access to poorly explored chemical space and has implications for drug discovery and the detection of chemically mediated biotic interactions.

11 July 2025 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
FBFeng Bao
Feng Bao
LLLi Li
Li Li
HHHeinz Hammerlindl
Heinz Hammerlindl
SSSusan Q. Shen
Susan Q. Shen
SHSabrina Hammerlindl
Sabrina Hammerlindl
LWLani F. Wu
Lani F. Wu

18 March 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
LLLi Li
Li Li
HHHeinz Hammerlindl
Heinz Hammerlindl
SSSusan Q. Shen
Susan Q. Shen
FBFeng Bao
Feng Bao
SHSabrina Hammerlindl
Sabrina Hammerlindl
LWLani F. Wu
Lani F. Wu
Severe acute hypoxic stress is a major contributor to the pathology of human diseases, including ischemic disorders. Current treatments focus on managing consequences of hypoxia, with few addressing cellular adaptation to low-oxygen environments. Here, we investigate whether accelerating hypoxia adaptation could provide a strategy to alleviate acute hypoxic stress. We develop a high-content phenotypic screening platform to identify compounds that fast-track adaptation to hypoxic stress. Our platform captures a high-dimensional phenotypic hypoxia response trajectory consisting of normoxic, acutely stressed, and chronically adapted cell states. Leveraging this trajectory, we identify compounds that phenotypically shift cells from the acutely stressed state towards the adapted state, revealing mTOR/PI3K or BET inhibition as strategies to induce this phenotypic shift. Importantly, our compound hits promote the survival of liver cells exposed to ischemia-like stress, and rescue cardiomyocytes from hypoxic stress. Our “phenopushing” platform offers a general, target-agnostic approach to identify compounds and targets that accelerate cellular adaptation, applicable across various stress conditions.

28 October 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
ABAurelie Benfield
Aurelie Benfield
FVFelicitas Vernen
Felicitas Vernen
RYReuben S.E. Young
Reuben S.E. Young
FNFerran Nadal-Bufí
Ferran Nadal-Bufí
HHHeinz Hammerlindl
Heinz Hammerlindl
SHSonia Troeira Henriques
Sonia Troeira Henriques
Acquired drug-resistance is a recurring problem in cancer treatment, and this is particularly true for patients with metastatic melanoma that carry a BRAF V600E mutation. In the current study, we explored the use of membrane-active peptides as an alternative therapeutic modality to target drug-resistant melanoma cells. We produced slow-cycling and drug-resistant melanoma cells using dabrafenib, a small molecule drug that targets tumor cells with BRAF V600E mutation, and characterised their lipidome and proteome to investigate the role of membrane lipids in acquired drug-resistance. Despite some changes in the lipid composition, tested anti-melanoma membrane-active cyclic peptides (cTI and cGm) killed melanoma cells that are sensitive, tolerant, or resistant to dabrafenib. Importantly, melanoma cells did not develop resistance to cTI or cGm, nor changed their lipid composition with long-term peptide treatment. Therefore, these peptides are well suited as templates to design therapeutic leads to target drug-resistant metastatic melanoma cells and/or as co-treatment with small molecule drugs.

7 September 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
QZQinghe Zeng
Qinghe Zeng
LFLandon Flemming
Landon Flemming
YCYuanzhou Chen
Yuanzhou Chen
TMThomas Mazumder
Thomas Mazumder
HHHeinz Hammerlindl
Heinz Hammerlindl
XHXiao Huang
Xiao Huang
T cell proliferative capacity and persistence determine the therapeutic efficacy of chimeric antigen receptor (CAR) T cells. However, strategies to externally enhance CAR-T cell expansion without genetic rewiring are lacking. Here, we engineer CAREp, programmable DNA-scaffolded PLGA microparticles displaying CAR-targeting antigens and CD28-costimulatory antibodies, to repeatedly stimulate human CD8+ CAR-T cells ex vivo. CAREp sustains a-EGFR CAR-T cell expansion for over 100 days across both 4-1BBζ and CD28ζ constructs, achieving up to 1018-fold cumulative expansion and surpassing tumor-cell or CD3/CD28-Dynabeads stimulation. Expanded cells retain effector function and mitochondrial fitness while exhibiting clonal enrichment, initially preserved memory-associated progenitor states, delayed exhaustion, and transiently activated telomerase delaying telomere attrition. Early transcriptomic responses show coordinated activation of DNA repair, chromatin remodeling, telomere maintenance, and mitochondrial function while restricting differentiation-associated signaling programs, mirroring long-term functional outcomes. These findings demonstrate that nanoscale ligand organization synchronizes acute CAR-T signaling with durable proliferative and metabolic states.

29 January 2020
Verified
Thesis
Closed access
HHHeinz Hammerlindl
Heinz Hammerlindl
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.